CD105 Antibody, anti-human

Name: CD105 Antibody, anti-human
Availability: InStock

CD105 Antibody, anti-humanExtended Validation

Clone:

43A4E1

Type of antibody:

Primary antibodies

Isotype:

mouse IgG1κ

Applications:

FC, MICS, IF, IHC

Alternative names:

ENG, END, HHT1, ORW1

Flow cytometry applications forCD105 Antibody, anti-human

APC
Biotin
FITC
PE
PE-Vio 770
VioBlue

Conjugate:

APC

Recommended dilution:

1:11

Remark:

Cells should be stained prior to fixation, if formaldehyde is used as a fixative.

Tested:

QC tested

Reported:

26850072, 28049638, 28231550, all publications

Products used:

130-099-125, 130-094-926

Protocols:

Cell surface flow cytometry staining protocol (PBS/EDTA/BSA 1:11)

Description:

Human peripheral blood mononuclear cells (PBMCs) were spiked with human umbilical vein endothelial cells (HUVECs) and stained with CD105 antibodies as well as with CD45 antibodies and analyzed by flow cytometry using the MACSQuant^® Analyzer. The Tandem Signal Enhancer has been used to increase binding specificity of tandem-dye–conjugated antibodies. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates.

MICS (MACSima Imaging Cyclic Staining) applications forCD105 Antibody, anti-human

APC
FITC
PE

Conjugate:

APC

Recommended dilution:

1:11

Fixation:

PFA

Tested:

during development

Species tested:

human

Products used:

130-099-125, 130-094-926

Compatible applications:

IF, IHC

Protocols:

Protocol for MICS experiments

Conjugate:

APC

Recommended dilution:

1:11

Fixation:

Acetone

Tested:

during development

Species tested:

human

Products used:

130-099-125, 130-094-926

Compatible applications:

IF, IHC

Protocols:

Protocol for MICS experiments

Extended validation for CD105 Antibody, anti-human

Sensitivity

Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Flow cytometric comparison of different clones for CD105. HUVECs were stained with CD105 antibodies and plotted against the side scatter. As a control, CD105 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Flow cytometric comparison of different clones for CD105. HUVECs were stained with CD105 antibodies and plotted against the side scatter. As a control, CD105 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Flow cytometric comparison of different clones for CD105. HUVECs were stained with CD105 antibodies and plotted against the side scatter. As a control, CD105 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Flow cytometric comparison of different clones for CD105. HUVECs were stained with CD105 antibodies and plotted against the side scatter. As a control, CD105 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Flow cytometric comparison of different clones for CD105. HUVECs were stained with CD105 antibodies and plotted against the side scatter. As a control, CD105 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Flow cytometric comparison of different clones for CD105. HUVECs were stained with CD105 antibodies and plotted against the side scatter. As a control, CD105 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Flow cytometric comparison of different clones for CD105. HUVECs were stained with CD105 antibodies and plotted against the side scatter. As a control, CD105 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Flow cytometric comparison of different clones for CD105. HUVECs were stained with CD105 antibodies and plotted against the side scatter. As a control, CD105 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Fixation data

To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.

No fixation

Post fixation

Comparison of staining pattern on non-fixed and fixed cells using CD105 (43A4E1). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Comparison of staining pattern on non-fixed and fixed cells using CD105 (43A4E1). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD105 Antibody, anti-human

Overview

The CD105 antigen, also known as endoglin, serves as a receptor for the growth and differentiation factors TGF-β1 and TGF-β3. An epitope of CD105 is recognized by the SH-2 antibody, which was raised against human mesenchymal stromal cells (MSCs) that show mesodermal differentiation capacity. Therefore, it can be used for studies on mesengenesis. CD105 is also expressed on mature endothelial cells and on some leukemic cells of B lymphoid and myeloid origin.

Alternative names

ENG, END, HHT1, ORW1

Detailed product information

Technical specifications

Clone	43A4E1
Clonality	monoclonal
Isotype	mouse IgG1κ
Isotype control	Isotype Control Antibody, mouse IgG1
Host	mouse
Type of antibody	Primary antibodies
Species	human
Antigen	CD105
Alternative names of antigen	ENG, END, HHT1, ORW1
Molecular mass of antigen [kDa]	68
Distribution of antigen	endothelial cells, monocytes, stem cells, leukemia cells, mesenchymal stem cells, bone marrow
Entrez Gene ID	2022
RRID	AB_2751408, AB_2661354, AB_2661355, AB_2661357, AB_10827601, AB_2661358, AB_2661359, AB_2661360, AB_2661361, AB_10828348, AB_2751426

Resources for CD105 Antibody, anti-human

Certificates

Please follow this

link

to search for Certificates of Analysis (CoA) by lot number.

References for CD105 Antibody, anti-human

Publications

Barry, F. P. et al. (1999) The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105). Biochem. Biophys. Res. Commun. 265: 134-139
Majumdar, M. K. et al. (2000) Isolation, characterization, and chondrogenic potential of human bone marrow-derived multipotential stromal cells. J. Cell. Physiol. 185: 98-106

Applications

Extended validation